Core Insights - EnWave Corporation reported consolidated interim financial results for Q1 2026, showing significant revenue growth and improvements in gross margin compared to the previous year [1][4]. Financial Performance - Revenues for Q1 2026 reached CAD 1,600,000, an increase of 36% from CAD 1,177,000 in Q1 2025, attributed to large-scale machine sales and increased royalties [2][4]. - Direct costs rose to CAD 1,006,000, up 20% from CAD 837,000 in the prior year [2]. - Gross margin improved to CAD 594,000, representing a 75% increase from CAD 340,000, with a gross margin percentage of 37% compared to 29% in Q1 2025 [2][4]. - Operating expenses totaled CAD 1,468,000, a 16% increase from CAD 1,268,000, driven by higher sales personnel and other costs [2][4]. - The net loss from continuing operations was CAD 1,108,000, an 18% increase from CAD 938,000 in the previous year [2][4]. - Adjusted EBITDA loss was CAD 585,000, showing an improvement of CAD 50,000 from CAD 635,000 in Q1 2025 [2][4]. Revenue Breakdown - Base royalties for Q1 2026 were CAD 500,000, an 18% increase from CAD 425,000 in the prior year [4]. - Total royalty revenue for Q1 2026 was CAD 627,000, a 12% increase from CAD 559,000 in Q1 2025, driven by more royalty partners and increased product sales [4]. Corporate Developments - EnWave signed several Commercial License Agreements (CLAs) with partners, including Gowen Gumlu Grower's Association in Australia and Shinyway International Limited in New Zealand, indicating expansion in its market presence [10][11]. - The company has developed a robust intellectual property portfolio and continues to innovate in vacuum microwave dehydration technology, enhancing its competitive edge in the food, pharmaceutical, and cannabis industries [8][9].

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&DFeb 19, 2026 7:00 PM Eastern Standard Time# Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&DShare---TOKYO & BASKING RIDGE, N.J.--([BUSINESS WIRE])--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026.Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiic ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying conditions revealed extreme volatility and market leadership. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Small Cap Strategy returned -1.89% net-of-fees, trailing the Russell 2000 Growth Index’s 1.22% return. The returns were volatile i ...

TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, is pleased to announce that the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”, see news releases dated January 13, 2026 and January 28, 2026) closed ...

Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Feb 19, 2026 6:30 AM Eastern Standard Time# Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Share---PIOMBINO DESE, Italy--([BUSINESS WIRE])-- [Stevanato Group S.p.A.](NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issu ...

Group 1: Healthcare Industry Overview - Healthcare industry stocks serve as effective hedges against technology and growth stocks, performing well when larger stock markets do not [1] - The performance of stocks varies by sub-industry, with some pharmaceutical and biotech stocks behaving more like growth stocks [1] Group 2: Novo Nordisk - Novo Nordisk is a leading global pharmaceutical company specializing in GLP-1 drugs for weight loss and diabetes management, alongside Eli Lilly [6] - In fiscal 2025, sales for diabetes and obesity care drugs increased by 7%, with obesity care drugs seeing a 26% gain; sales growth for 2026 is projected between 5% to 13% [7] - The GLP-1 market is expected to grow to $254 billion by 2034, representing a compound annual growth rate of 17%, positioning Novo Nordisk for long-term benefits [7] - The stock is currently trading at a low valuation of 13 times earnings, priced at $49 per share, making it an attractive investment option [8] Group 3: AbbVie - AbbVie, a spinoff from Abbott Labs, has demonstrated strong defensive characteristics, rising 24% during the 2022 bear market while the S&P 500 fell by 18% [9] - AbbVie has consistently increased its dividend for 13 years since its separation from Abbott, currently offering a high yield of 3.1% [9]

Core Insights - Amazon Pharmacy will expand its Same-Day prescription delivery service to nearly 4,500 U.S. cities and towns by the end of 2026, adding approximately 2,000 new communities this year [1] - The expansion aims to provide fast and reliable medication delivery to millions of customers, particularly in states like Idaho and Massachusetts, where access to pharmacy services has been historically limited [1] Delivery Speed Improvements - In 2025, Amazon Pharmacy recorded significant delivery speed improvements, utilizing various transportation methods including e-bikes in urban areas and ferries in remote locations [1] - Customers in Los Angeles were able to pick up medications within minutes using Amazon Pharmacy Kiosks located in primary care offices, facilitating immediate treatment [1] Accessibility and Support Features - Amazon Pharmacy introduced a caregiver support feature in 2025 to assist families in managing medications for loved ones and expanded its $5-per-month RxPass prescription savings program to Prime members in 48 states [1] - The service also includes 24/7 access to licensed pharmacists and automatic refills, addressing the needs of customers in underserved areas [1] Savings and Pricing Transparency - In 2025, Amazon Pharmacy helped customers save over $150 million by applying eligible manufacturer-sponsored coupons, with significant savings on insulin and GLP-1 medications [1] - Prime members can save up to 80% on generic medications and 40% on brand-name medications through Prime Rx, with additional access to over 50 commonly prescribed medications via the RxPass program [1] Overall Strategy - Amazon Pharmacy is focused on redefining customer expectations in pharmacy care by combining pharmacy expertise with a robust logistics network to enhance accessibility, affordability, and convenience [1]

Core Insights - Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026, focusing on its AI-driven oncology drug development [1] - The company’s RADR® platform has facilitated the development of LP-184 / STAR-001, a novel therapeutic candidate for CNS cancers, including recurrent glioblastoma and pediatric brain tumors [1] - STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation, highlighting its potential in treating rare conditions [1] Company Overview - Lantern Pharma is a clinical-stage biopharmaceutical company utilizing artificial intelligence and machine learning to enhance oncology drug discovery and development [1] - The RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug responses, and design more effective clinical trials [1] - The company’s pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations [1] Presentation Highlights - CEO Panna Sharma will discuss the application of RADR® in discovering novel combination therapies, selecting optimal cancer indications, identifying patient biomarkers, and elucidating the mechanism of action of STAR-001 during the summit [1] - The presentation will emphasize AI-driven insights that address challenges in treating aggressive brain cancers like glioblastoma and atypical teratoid/rhabdoid tumors (ATRT) [1]

Core Insights - Cencora reported a revenue of $85.9 billion for the first quarter of fiscal 2026, marking a 5.5% increase year-over-year, driven by growth in both U.S. and International Healthcare Solutions segments [1][2] - The company achieved a GAAP diluted EPS of $2.87, up 14.8% from $2.50 in the prior year, while adjusted diluted EPS rose 9.4% to $4.08 [1][3] - Cencora raised its adjusted operating income guidance for fiscal 2026 to a growth range of 11.5% to 13.5%, reflecting the acquisition of OneOncology and strong performance in the U.S. Healthcare Solutions segment [1][2] Financial Performance - Revenue for the U.S. Healthcare Solutions segment was $76.2 billion, a 5.0% increase year-over-year, attributed to market growth and increased sales of specialty products [2] - International Healthcare Solutions segment revenue reached $7.6 billion, up 9.6% year-over-year, primarily due to growth in the European distribution business [2] - Operating income for the U.S. Healthcare Solutions segment increased by 21.0% to $831.3 million, while the International Healthcare Solutions segment saw a decrease of 13.9% in operating income to $142.2 million [2] Segment Analysis - The U.S. Healthcare Solutions segment's growth was driven by unit volume growth and increased sales of diabetes and weight loss products, despite some losses from specific customers [2] - The International Healthcare Solutions segment's revenue growth was 6.2% on a constant currency basis, but operating income decreased by 17.0% due to challenges in the European distribution business [2] - Revenue from other businesses, including MWI Animal Health and Profarma, was $2.1 billion, reflecting a 6.3% increase, although operating income in this category decreased by 6.1% [2] Guidance and Expectations - Cencora reaffirmed its full fiscal 2026 adjusted diluted EPS guidance range of $17.45 to $17.75, reflecting the expected contributions from the OneOncology acquisition [2] - The company anticipates revenue growth of 7% to 9% across its segments, with adjusted operating income growth projected at 11.5% to 13.5% [2] - The adjusted effective tax rate is expected to be around 20% for fiscal 2026, with net interest expense projected between $480 million and $500 million [2]

Core Insights - Pfizer reported solid financial results for the full year 2025, with revenues of $62.6 billion, reflecting a 2% year-over-year operational decline, but a 6% operational growth excluding COVID-19 product contributions [1][2] - The company reaffirmed its financial guidance for 2026, expecting revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00 [1][2] - Pfizer's strategic focus includes approximately 20 key pivotal study starts planned for 2026, aimed at maximizing growth opportunities [1][2] Financial Performance - Full-year 2025 revenues were $62.6 billion, down from $63.6 billion in 2024, with a 2% operational decline [1][2] - Fourth-quarter 2025 revenues totaled $17.6 billion, a decrease of 1% compared to the prior year, with an operational decline of 3% [1][2] - Adjusted diluted EPS for 2025 was $3.22, reflecting a 4% increase from $3.11 in 2024 [1][2] Revenue Breakdown - The global biopharmaceuticals business saw a 2% decline in revenues for both the fourth quarter and full year [1][2] - Notable revenue growth was observed in products like Padcev (up 15%), Lorbrena (up 45%), and Abrysvo (up 136%) [1][2] - Significant declines were noted in Paxlovid (down 70%) and Comirnaty (down 35%) due to reduced COVID-19 infection rates and vaccination recommendations [1][2] Capital Allocation - In 2025, Pfizer invested approximately $8.8 billion in business development transactions and $10.4 billion in internal R&D projects [1][2] - The company returned $9.8 billion to shareholders through cash dividends, with no share repurchases completed in 2025 [1][2] - Pfizer's remaining share repurchase authorization as of February 3, 2026, is $3.3 billion, with no share repurchases anticipated in 2026 [1][2] Strategic Developments - Pfizer announced several key product developments, including positive Phase 3 results for Braftovi and Hympavzi, and advancements in its obesity treatment pipeline [2] - The company completed the acquisition of Metsera for approximately $7.0 billion, enhancing its portfolio in obesity and cardiometabolic diseases [2] - Pfizer also reached an agreement to exit its investment in ViiV Healthcare Limited for $1.875 billion [2]